Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4629-4635

  Li, Liang ^a   Zhang, Xuening ^a   Xia, Qinglai ^a   Ma, Hui ^a   Chen, Li ^a   Hou, Wenjing ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Association; Estrogen receptor alpha; Meta analysis; Prostate cancer; PvuII polymorphism

Indexed keywords

ESTROGEN RECEPTOR ALPHA; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA MODIFICATION METHYLASE PVUII; ESTROGEN RECEPTOR ALPHA, HUMAN;

ALLELE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY ANALYSIS; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; PROSTATE TUMOR; PUBLISHING; RISK;

DNA-CYTOSINE METHYLASES; ESTROGEN RECEPTOR ALPHA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK;

EID: 84902963681     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1606-9     Document Type: Article

References (33)

1. Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634.
2. Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a metaanalysis. PLoS One. 2013;8:e69366.
3. Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.
4. Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS One. 2013;8:e58170.
5. Zhang H, Xu Y, Zhang Z, Li L. The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls. BMC Cancer. 2011;11:391.
6. Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 1988;7:3385-8.
7. Beleza-Meireles A, Omrani D, Kockum I, Frisen L, Lagerstedt K, et al. Polymorphisms of estrogen receptor beta gene are associated with hypospadias. J Endocrinol Investig. 2006;29:5-10. (Pubitemid 43361419)
8. Sobti RC, Gupta L, Singh SK, SethA, Kaur P, et al. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet. 2008;185:78-85.
9. Gupta L, Thakur H, Sobti RC, Seth A, Singh SK. Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population. Mol Cell Biochem. 2010;335:255-61.
10. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012;51 Suppl 1:E104-17.
11. Szendroi A, Speer G, Tabak A, Kosa JP, Nyirady P, et al. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can J Urol. 2011;18:5710-6.
12. Balistreri CR, Caruso C, Carruba G, Miceli V, Candore G. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study. OMICS. 2011;15:369-74.
13. Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, et al. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011;96:E368-72.
14. Sonoda T, Suzuki H, Mori M, Tsukamoto T, Yokomizo A, et al. Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanesemen. Eur J Cancer Prev. 2010;19:131-7.
15. Onsory K, Sobti RC, Al-Badran AI, Watanabe M, Shiraishi T, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem. 2008;314:25-35.
16. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, et al. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer. 2006;56:31-9. (Pubitemid 46173412)
17. Hernández J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006;175:523-7. (Pubitemid 43067344)
18. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 2004;24:2431-7. (Pubitemid 39166328)
19. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer. 2003;98:1411-6. (Pubitemid 37151495)
20. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, et al. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog. 2003;37:202-8. (Pubitemid 36959536)
21. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res. 2001;7:3092-6. (Pubitemid 32963829)
22. Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56.
23. Zhang H, Qi C, Wang A, Li L, Xu Y. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer. Tumor Biol. 2013. doi:10.1007/s13277-013-1268-z.
24. Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77.
25. Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res. 2012;31:53.
26. Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012;33:1335-9.
27. Findeisen P, Costina V, Yepes D, Hofheinz R, Neumaier M. Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability. J Exp Clin Cancer Res. 2012;31:56.
28. Jancik S, Drabek J, Berkovcova J, Xu YZ, Stankova M, Klein J, et al. A comparison of direct sequencing, pyrosequencing, high resolution melting analysis, TheraScreen DxS, and the K-ras Strip Assay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res. 2012;31:79.
29. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31:71.
30. Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biol. 2012;33:1291-8.
31. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31:16.
32. Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, et al. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res. 2013;32:25.
33. Macuks R, Baidekalna I, Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumor Biol. 2012;33(5):1811-7.